We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Investors, however, should not place too much weight on these developments alone. While the NIH initiative could accelerate cancer-vaccine research and Nasdaq-100 inclusion could boost demand for MRNA shares, these catalysts are ultimately secondary to Moderna’s ability to advance its pipeline and demonstrate clinical success. Sustained growth will depend on the company’s ability to translate promising research into approved treatments and, eventually, commercial success.
Let’s take a closer look at Moderna’s fundamentals to assess whether the stock remains attractive following its recent rally.
Oncology Is Emerging as a Key Growth Driver for MRNA
Moderna’s stock has become the best performer in the S&P 500 in 2026, primarily driven by positive intismeran results.
In August, Moderna reported positive results from the phase III INTerpath-001 study evaluating intismeran plus Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma patients whose tumors had been removed through surgery. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
Although detailed data from the study have yet to be disclosed, a fuller presentation is expected later this month. The reported findings strengthen the case for intismeran as a potential oncology growth opportunity for Moderna.
The potential opportunity extends beyond melanoma. Moderna and Merck are also evaluating intismeran in other cancer types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Positive results across these programs could broaden the therapy’s commercial potential and establish oncology as an important growth avenue beyond Moderna’s vaccine portfolio. However, realizing this opportunity will depend on further clinical progress, regulatory approvals and the eventual commercialization of the therapy.
This development has also raised investor interest in other investigational approaches that Moderna is developing to broaden its oncology pipeline. These include cancer antigen therapies, T-cell engagers and cell-therapy enhancers. The company is also exploring earlier-stage technologies, such as in-vivo CAR-T and CAR-M cell therapies, which could create further growth opportunities over the longer term.
Respiratory Vaccines Offer Another Avenue for Growth
Moderna’s respiratory business is gradually evolving beyond its COVID-19 vaccine franchise. The company has expanded into RSV with mResvia and recently entered the seasonal influenza market with mFlusiva. This gives Moderna a presence across three major respiratory vaccine categories and should gradually reduce its reliance on COVID demand.
The company has also expanded its portfolio into combination vaccines with mCombriax, which protects against both influenza and COVID-19 in a single shot. The vaccine received approval in the European Union in April 2026, marking an important milestone in Moderna’s efforts to broaden its respiratory franchise.
Commercial execution is now becoming the key focus. mFlusiva is expected to be available for the 2026/2027 U.S. respiratory season, while Moderna is preparing to launch mCombriax in Europe next year. Management views Europe as a significant growth opportunity, particularly as a competitor’s COVID-19 vaccine contract is set to expire at the end of 2026. The company is also seeking broader international reach through long-term partnerships and regulatory expansion in markets outside the United States. In the United States, Moderna is awaiting FDA guidance on refiling mCombriax, leaving another potential avenue to extend the combination-vaccine franchise.
The broader respiratory pipeline provides additional avenues for expansion, with norovirus and bird flu vaccines in late-stage development.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.
In oncology, the challenge is broader than competing for market share in a single indication. BioNTech is also developing an individualized mRNA-based cancer immunotherapy in collaboration with Roche, putting the two companies on a path to compete in the emerging personalized oncology market. As Moderna seeks to expand intismeran across multiple tumor types, its ability to differentiate the therapy, secure regulatory approvals and execute a successful commercial launch will be critical to realizing its potential.
MRNA Stock Performance, Valuation & Estimates
Year to date, MRNA stock has skyrocketed 625% compared with the industry’s nearly 2% growth, as seen in the chart below. During this timeframe, the stock has also outperformed the broader Medical sector and the S&P 500 Index.
MRNA Stock Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, Moderna appears to be trading at a significant premium compared to the industry. Based on the price/sales (P/S) ratio, the company’s shares currently trade at 33.49 times trailing 12-month sales, higher than 2.06 for the industry.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss per share have widened from $8.50 to $8.52 in the past 30 days. However, those for 2027 have narrowed from $4.52 to $4.46 during the same period.
Image Source: Zacks Investment Research
How to Play MRNA Stock?
Moderna’s prospects have improved following the positive cancer therapy results, which strengthen its potential to evolve beyond a COVID-19 vaccine maker into a diversified pharmaceutical company. However, that transition will take time as the company advances its oncology pipeline and builds commercial traction for newer products.
Meanwhile, MRNA’s sharp rally has pushed its valuation to a significant premium over the industry and even Big Pharma. With the company still reporting losses, this elevated valuation leaves the stock vulnerable if clinical progress or commercial growth falls even slightly short of expectations.
Given the steep gains and premium valuation, short-term investors may be better off booking profits or staying on the sidelines until a more attractive entry point emerges. Long-term investors, however, may consider holding their positions to benefit from this Zacks Rank #3 (Hold) company’s evolving growth opportunities, while recognizing that the turnaround will not happen overnight.
View the Zacks #1 Rank List
Image: Shutterstock
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Key Takeaways
Shares of Moderna (MRNA - Free Report) have gained more than 5% over the past week, adding roughly $4.2 billion in market value.
The upside reflects two catalysts — reports of a planned National Institutes of Health (NIH)-backed initiative to accelerate cancer-vaccine research and the company’s recent addition to the Nasdaq-100 Index, which could drive incremental demand from index-tracking funds.
While these developments appear unrelated, both are underpinned by growing optimism around Moderna’s personalized mRNA-based cancer therapy, intismeran autogene, following positive phase III results in melanoma. The candidate is being developed in partnership with Merck (MRK - Free Report) .
Investors, however, should not place too much weight on these developments alone. While the NIH initiative could accelerate cancer-vaccine research and Nasdaq-100 inclusion could boost demand for MRNA shares, these catalysts are ultimately secondary to Moderna’s ability to advance its pipeline and demonstrate clinical success. Sustained growth will depend on the company’s ability to translate promising research into approved treatments and, eventually, commercial success.
Let’s take a closer look at Moderna’s fundamentals to assess whether the stock remains attractive following its recent rally.
Oncology Is Emerging as a Key Growth Driver for MRNA
Moderna’s stock has become the best performer in the S&P 500 in 2026, primarily driven by positive intismeran results.
In August, Moderna reported positive results from the phase III INTerpath-001 study evaluating intismeran plus Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma patients whose tumors had been removed through surgery. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
Although detailed data from the study have yet to be disclosed, a fuller presentation is expected later this month. The reported findings strengthen the case for intismeran as a potential oncology growth opportunity for Moderna.
The potential opportunity extends beyond melanoma. Moderna and Merck are also evaluating intismeran in other cancer types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Positive results across these programs could broaden the therapy’s commercial potential and establish oncology as an important growth avenue beyond Moderna’s vaccine portfolio. However, realizing this opportunity will depend on further clinical progress, regulatory approvals and the eventual commercialization of the therapy.
This development has also raised investor interest in other investigational approaches that Moderna is developing to broaden its oncology pipeline. These include cancer antigen therapies, T-cell engagers and cell-therapy enhancers. The company is also exploring earlier-stage technologies, such as in-vivo CAR-T and CAR-M cell therapies, which could create further growth opportunities over the longer term.
Respiratory Vaccines Offer Another Avenue for Growth
Moderna’s respiratory business is gradually evolving beyond its COVID-19 vaccine franchise. The company has expanded into RSV with mResvia and recently entered the seasonal influenza market with mFlusiva. This gives Moderna a presence across three major respiratory vaccine categories and should gradually reduce its reliance on COVID demand.
The company has also expanded its portfolio into combination vaccines with mCombriax, which protects against both influenza and COVID-19 in a single shot. The vaccine received approval in the European Union in April 2026, marking an important milestone in Moderna’s efforts to broaden its respiratory franchise.
Commercial execution is now becoming the key focus. mFlusiva is expected to be available for the 2026/2027 U.S. respiratory season, while Moderna is preparing to launch mCombriax in Europe next year. Management views Europe as a significant growth opportunity, particularly as a competitor’s COVID-19 vaccine contract is set to expire at the end of 2026. The company is also seeking broader international reach through long-term partnerships and regulatory expansion in markets outside the United States. In the United States, Moderna is awaiting FDA guidance on refiling mCombriax, leaving another potential avenue to extend the combination-vaccine franchise.
The broader respiratory pipeline provides additional avenues for expansion, with norovirus and bird flu vaccines in late-stage development.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.
In oncology, the challenge is broader than competing for market share in a single indication. BioNTech is also developing an individualized mRNA-based cancer immunotherapy in collaboration with Roche, putting the two companies on a path to compete in the emerging personalized oncology market. As Moderna seeks to expand intismeran across multiple tumor types, its ability to differentiate the therapy, secure regulatory approvals and execute a successful commercial launch will be critical to realizing its potential.
MRNA Stock Performance, Valuation & Estimates
Year to date, MRNA stock has skyrocketed 625% compared with the industry’s nearly 2% growth, as seen in the chart below. During this timeframe, the stock has also outperformed the broader Medical sector and the S&P 500 Index.
MRNA Stock Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, Moderna appears to be trading at a significant premium compared to the industry. Based on the price/sales (P/S) ratio, the company’s shares currently trade at 33.49 times trailing 12-month sales, higher than 2.06 for the industry.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss per share have widened from $8.50 to $8.52 in the past 30 days. However, those for 2027 have narrowed from $4.52 to $4.46 during the same period.
Image Source: Zacks Investment Research
How to Play MRNA Stock?
Moderna’s prospects have improved following the positive cancer therapy results, which strengthen its potential to evolve beyond a COVID-19 vaccine maker into a diversified pharmaceutical company. However, that transition will take time as the company advances its oncology pipeline and builds commercial traction for newer products.
Meanwhile, MRNA’s sharp rally has pushed its valuation to a significant premium over the industry and even Big Pharma. With the company still reporting losses, this elevated valuation leaves the stock vulnerable if clinical progress or commercial growth falls even slightly short of expectations.
Given the steep gains and premium valuation, short-term investors may be better off booking profits or staying on the sidelines until a more attractive entry point emerges. Long-term investors, however, may consider holding their positions to benefit from this Zacks Rank #3 (Hold) company’s evolving growth opportunities, while recognizing that the turnaround will not happen overnight.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.